You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.

Tag:

triple negative breast cancer x

Triple negative breast cancer (TNBC) is so named because TNBC cells lack the three common breast tumor markers:  estrogen receptor, progesterone receptor and the HER2 protein.  Unlike breast cancers with these markers, there are currently no FDA-approved targeted therapies for TNBC.

Triple negative breast cancer (TNBC) comprises 15-20 percent of all breast cancers, but few treatment options exist outside of chemotherapy.

Using only a blood test, researchers have identified a biomarker that can predict prognosis in patients with metastatic triple negative breast cancer (mTNBC).

Most clinical studies collect blood, tumor samples, or other tissue from participants. While this data is important for the study at hand, the samples may help future studies as well.

Dr. Leisha Emens is at the Johns Hopkins Kimmel Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy.

After studying immunology as a graduate student, Dr. Robert Vonderheide was so amazed by its complexity and potential in medicine that he decided to go to medical school. As a medical oncologist, Dr.

To mark Triple Negative Breast Cancer Day, BCRF recently met with two of its expert researchers in immuno-oncology to learn more about the progress and challenges of immunotherapy in triple negative breast cancer and other

On Triple Negative Breast Cancer Day, the breast cancer community highlights a subtype of the disease defined by its aggressive nature and limited treatment options.

Triple negative breast cancer (TNBC) accounts for approximately 15 percent of all breast cancers.

When Rochelle Barr first heard the words “triple negative breast cancer,” she was optimistic about her prognosis. After all, in the medical world, testing negative is usually considered a good thing.